biotech / news / / Firstpost
Keytruda, an immunotherapy drug, is being used to treat at least 19 types of tumours.
An ICIJ investigation found Merck used lobbying to keep Keytruda prices high globally.
KEY POINTS
- Keytruda's primary patent expires in 2028, but follow-on patents could extend monopoly until 2042.
- Generic versions could reduce Keytruda's cost by up to 70% after patent expiry.
- A black market for counterfeit Keytruda has emerged in India, involving hospital staff and refilled vials.
COMPANIES
Summarized by Newsio from Firstpost. How we summarize →